ENGINEERED MULTIVALENCY FOR ENHANCED AFFIBODY-BASED HER3 CANCER THERAPYJohn S. Schardt(University of Michigan)Digital Repository at the University of Maryland (University of Maryland College Park)January 1, 201810.13016/m2q23r36bCited by 1SaveCiteExport RISWatch citationsRelated PapersDiscovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening|Scientific Reports|2021|24